Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1990; 15:691-697
© 1990 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knudtson, M.
Right arrow Articles by Duff, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knudtson, M.
Right arrow Articles by Duff, H.

Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty

ML Knudtson, VF Flintoft, DL Roth, JL Hansen, and HJ Duff

Department of Medicine, University of Calgary, Alberta, Canada.

The effect of short-term prostacyclin (PGI2) administration on the incidence of restenosis after coronary angioplasty was studied in a prospective single-blind randomized trial of 286 patients. Of the 270 patients in whom dilation was successful, 134 received prostacyclin and 136 received placebo. Intracoronary prostacyclin was administered before and after dilation and then intravenously for 48 h. The control group received intracoronary placebo infusions before and after dilation. All patients received aspirin and dipyridamole before and after angioplasty, at least until follow-up angiography. Follow-up angiograms were obtained in 93% of patients in whom angioplasty was successful. Restenosis of one or more lesions was present in 34 patients (27%) who were given prostacyclin compared with 40 patients (32%) in the control group (p = NS). Acute vessel closure and ventricular tachyarrhythmias were more common in the control group than in the patients who received prostacyclin (acute vessel closure occurred in 14 [10.3%] of 136 versus 4 [3.0%] of 134, respectively, p less than 0.01; ventricular tachyarrhythmias occurred in 5 [3.4%] of 147 versus 0 of 139 respectively, p less than 0.05). Short-term administration of prostacyclin did not significantly lower the risk of restenosis after coronary angioplasty.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
R. S. Wright, J. L. Anderson, C. D. Adams, C. R. Bridges, D. E. Casey Jr, S. M. Ettinger, F. M. Fesmire, T. G. Ganiats, H. Jneid, A. M. Lincoff, et al.
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., May 10, 2011; 57(19): 1920 - 1959.
[Full Text] [PDF]


Home page
CirculationHome page
2011 Writing Group Members, R. S. Wright, J. L. Anderson, C. D. Adams, C. R. Bridges, D. E. Casey Jr, S. M. Ettinger, F. M. Fesmire, T. G. Ganiats, H. Jneid, et al.
2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation, May 10, 2011; 123(18): 2022 - 2060.
[Full Text] [PDF]


Home page
ChestHome page
R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington
The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 776S - 814S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz
Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 576S - 599S.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
S. V. Dee and H. Samady
Evolving Strategies for the Prevention and Treatment of Coronary Restenosis
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 281 - 293.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al.
ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions
J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239.
[Full Text] [PDF]


Home page
ChestHome page
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger
Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention
Chest, January 1, 2001; 119(2009): 321S - 336S.
[Full Text] [PDF]


Home page
CirculationHome page
E. Alt, I. Haehnel, C. Beilharz, K. Prietzel, D. Preter, A. Stemberger, T. Fliedner, W. Erhardt, and A. Schomig
Inhibition of Neointima Formation After Experimental Coronary Artery Stenting : A New Biodegradable Stent Coating Releasing Hirudin and the Prostacyclin Analogue Iloprost
Circulation, March 28, 2000; 101(12): 1453 - 1458.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. A. Stouffer, Z. Hu, M. Sajid, H. Li, G. Jin, M. T. Nakada, S. R. Hanson, and M. S. Runge
3 Integrins Are Upregulated After Vascular Injury and Modulate Thrombospondin- and Thrombin-Induced Proliferation of Cultured Smooth Muscle Cells
Circulation, March 10, 1998; 97(9): 907 - 915.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
P. K. Shah
New Antithrombotic Drugs for Coronary Artery Disease
Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 165 - 176.
[PDF]


Home page
ScienceHome page
T Ohno, D Gordon, H San, V. Pompili, M. Imperiale, G. Nabel, and E. Nabel
Gene therapy for vascular smooth muscle cell proliferation after arterial injury
Science, August 5, 1994; 265(5173): 781 - 784.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement